Teppei Matsumoto
Hirosaki University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Teppei Matsumoto.
BMC Urology | 2017
Toshikazu Tanaka; Shingo Hatakeyama; Hayato Yamamoto; Takuma Narita; Itsuto Hamano; Teppei Matsumoto; Osamu Soma; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Ippei Takahashi; Shigeyuki Nakaji; Yuriko Terayama; Tomihisa Funyu; Chikara Ohyama
BackgroundThe aim of the present study is to investigate the clinical relevance of aortic calcification in urolithiasis patients.MethodsBetween January 2010 and September 2014, 1221 patients with urolithiasis were treated in Oyokyo Kidney Research Institute and Hirosaki University Hospital. Among these, 287 patients (Stone group) on whom adequate data were available were included in this retrospective study. We also selected 148 subjects with early stage (pT1N0M0) renal cell carcinoma from 607 renal cell carcinoma patients who underwent radical nephrectomy at Hirosaki University Hospital (Non-stone group) as control subjects. Validity of the Non-stone group was evaluated by comparison with pair-matched 296 volunteers from 1166 subjects who participated in the Iwaki Health Promotion Project in 2014. Thereafter, age, body mass index, aortic calcification index (ACI), renal function, serum uric acid concentrations, and comorbidities (diabetes, hypertension, or cardiovascular disease) were compared between the Non-stone and Stone groups. Independent factors for higher ACI and impaired renal function were assessed using multivariate logistic regression analysis.ResultsWe confirmed relevance of Non-stone group patients as a control subject by comparing the pair-matched community-dwelling volunteers. Backgrounds of patients between the Non-stone and Stone groups were not significantly different except for the presence of hypertension in the Stone group. ACI was not significantly high in the Stone group compared with the Non-stone group. However, age-adjusted ACI was greater in the Stone group than the Non-stone group. Among urolithiasis patients, ACI was significantly higher in uric acid containing stone patients. The number of patients with stage 3B chronic kidney disease (CKD) was significantly higher in the Stone group than in the Non-stone group (12% vs. 4%, P = 0.008). Multivariate logistic regression analysis showed higher aortic calcification index (>13%), and being a stone former were independent factors for stage 3B CKD at the time of diagnosis.ConclusionAortic calcification and being a stone former had harmful influence on renal function. This study was registered as a clinical trial: UMIN: UMIN000022962.
PLOS ONE | 2017
Yoshimi Tanaka; Shingo Hatakeyama; Toshikazu Tanaka; Hayato Yamamoto; Takuma Narita; Itsuto Hamano; Teppei Matsumoto; Osamu Soma; Teppei Okamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Ippei Takahashi; Shigeyuki Nakaji; Yuriko Terayama; Tomihisa Funyu; Chikara Ohyama
Objectives To determine the influence of serum uric acid (UA) levels on renal impairment in patients with UA stone. Materials and methods We retrospectively analyzed 463 patients with calcium oxalate and/or calcium phosphate stones (CaOx/CaP), and 139 patients with UA stones. The subjects were divided into the serum UA-high (UA ≥ 7.0 mg/dL) or the UA-low group (UA < 7.0 mg/dL). The control group comprised 3082 community-dwelling individuals that were pair-matched according to age, sex, body mass index, comorbidities, hemoglobin, serum albumin, and serum UA using propensity score matching. We compared renal function between controls and patients with UA stone (analysis 1), and between patients with CaOx/CaP and with UA stone (analysis 2). Logistic regression analysis was used to evaluate the impact of the hyperuricemia on the development of stage 3 and 3B chronic kidney disease (CKD) (analysis 3). Results The renal function was significantly associated with serum UA levels in the controls and patients with CaOx/CaP and UA stones. In pair-matched subgroups, patients with UA stone had significantly lower renal function than the control subjects (analysis 1) and patients with CaOx/CaP stones (analysis 2) regardless of hyperuricemia. Multivariate logistic regression analysis revealed that patients with UA stone, CaOx/CaP, hyperuricemia, presence of cardiovascular disease, higher body mass index, older age and lower hemoglobin had significantly higher risk of stage 3 and 3B CKD (analysis 3). Conclusion Patients with UA stones had significantly worse renal function than controls and CaOx/CaP patients regardless of hyperuricemia. Urolithiasis (CaOx/CaP and UA stone) and hyperuricemia had an association with impaired renal function. Our findings encourage clinicians to initiate intensive treatment and education approaches in patients with urolithiasis and/or hyperuricemia in order to prevent the progression of renal impairment.
Oncotarget | 2017
Hirotake Kodama; Shingo Hatakeyama; Naoki Fujita; Hiromichi Iwamura; Go Anan; Ken Fukushi; Takuma Narita; Toshikazu Tanaka; Yuka Kubota; Hirotaka Horiguchi; Masaki Momota; Koichi Kido; Teppei Matsumoto; Osamu Soma; Itsuto Hamano; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Atsushi Sasaki; Toshiaki Kawaguchi; Makoto Sato; Chikara Ohyama
Objective To evaluate the impact of preoperative chronic kidney disease (CKD) on oncological outcomes in patients with upper tract urothelial carcinoma who underwent radical nephroureterectomy. Methods A total of 426 patients who underwent radical nephroureterectomy at five medical centers between February 1995 and February 2017 were retrospectively examined. Oncological outcomes, including intravesical recurrence-free, visceral recurrence-free, cancer-specific, and overall survival rates (intravesical RFS, visceral RFS, CSS, and OS, respectively) stratified by preoperative CKD status (CKD vs. non-CKD) were investigated. Cox proportional hazards regression analysis was performed using inverse probability of treatment weighting (IPTW) to evaluate the impact of preoperative CKD on prognosis and a prognostic factor-based risk stratification nomogram was developed. Results Of the 426 patients, 250 (59%) were diagnosed with CKD before radical nephroureterectomy. Before the background adjustment, intravesical RFS, visceral RFS, CSS, and OS after radical nephroureterectomy were significantly shorter in the CKD group than in the non-CKD group. Background-adjusted IPTW analysis demonstrated that preoperative CKD was significantly associated with poor visceral RFS, CSS, and OS after radical nephroureterectomy. Intravesical RFS was not significantly associated with preoperative CKD. The nomogram for predicting 5-year visceral RFS and CSS probability demonstrated a significant correlation with actual visceral RFS and CSS (c-index = 0.85 and 0.83, respectively). Conclusions Upper tract urothelial carcinoma patients with preoperative CKD had a significantly lower survival probability than those without CKD.
Case reports in urology | 2015
Shogo Hosogoe; Osamu Soma; Teppei Matsumoto; Atsushi Imai; Shingo Hatakeyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama; Masahiko Aoki
A 47-year-old Japanese man was diagnosed with prostate cancer in February 1995 (Initial PSA 77.2 ng/mL, GS3 + 4, cT3N0M0). He underwent radical prostatectomy after androgen deprivation therapy (ADT) in June 1995. Nine years after operation, he was diagnosed with local recurrence of prostate cancer and he received postoperative external beam radiation therapy (EBRT) (70 Gy). By May 2008, the PSA dropped to 0.33 ng/mL, and a CT scan showed that the mass had disappeared. On April 2012, the PSA once again rose to 3.1 ng/mL. CT scan and MRI revealed a mass in the prostatic bed. We diagnosed local recurrence of prostate cancer. We underwent salvage low-dose brachytherapy after obtaining informed consent. The prescribed dose of the salvage brachytherapy was 145 Gy to control the tumor considering the hormone resistant prostatic cancer and high-risk feature. PSA level rapidly decreased to 0.66 ng/mL by 6 months after seed implantation. No adverse events were seen during the follow-up period.
Oncotarget | 2018
Osamu Soma; Shingo Hatakeyama; Teppei Okamoto; Naoki Fujita; Teppei Matsumoto; Yuki Tobisawa; Tohru Yoneyama; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Shigeyuki Nakaji; Chikara Ohyama
Objectives Optimal tools for evaluating frailty among urological cancer patients remain unclear. We aimed to develop a quantitative frailty assessment tool comparing healthy individuals and urological cancer patients, and investigate the clinical implication of quantitative frailty on prognosis in urological cancer patients. Results Gait speed, hemoglobin, serum albumin, exhaustion, and depression were significantly worse in patients with all types of cancers than in pair-matched controls. Frailty discriminant score (FDS) showed clear separation between controls and urological cancer patients, and significant association with the Fried criteria. Overall survivals were significantly shorter in patients with a higher score (>2.30) than in those with a lower score among nonprostate cancer (bladder, upper tract urothelial carcinoma, and renal cell carcinoma) patients. In prostate cancer patients, overall survivals were significantly shorter in patients with a higher score (>3.30) than in those with a lower score. Conclusions FDS was significantly associated with frailty and prognosis in urological cancer patients. This tool for frailty assessment can help patients and physicians make more informed decisions. Further validation study is needed. Materials and Methods Total 605 urological cancer patients presenting to our hospital underwent a prospective frailty assessment. Controls were selected from 2280 community-dwelling subjects. Frailty was assessed via physical status, blood biochemical tests, and mental status. We compared frailty variables between pair-matched controls and urological cancer patients. We developed FDS using frailty variables, and compared with the Fried criteria. The influence of FDS on overall survivals was investigated by Kaplan-Meier analysis and Cox regression analysis.
Transplantation Proceedings | 2018
H. Mursawa; Shingo Hatakeyama; Hayato Yamamoto; Yoshimi Tanaka; Osamu Soma; Teppei Matsumoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Takeshi Fujita; Reiichi Murakami; Hisao Saitoh; Takashi Suzuki; Shunji Narumi; Chikara Ohyama
PURPOSE Pre-emptive kidney transplantation (PKT) is expected to improve graft and cardiovascular event-free survival compared with standard kidney transplantation. Aortic calcification is reported to be closely associated with renal dysfunction and cardiovascular events; however, its implication in PKT recipients remains incompletely explored. This aim of this study was to evaluate whether PKT confers a protective effect on aortic calcification, renal function, graft survival, and cardiovascular event-free survival. METHODS One hundred adult patients who underwent renal transplantation between January 1996 and March 2016 at Hirosaki University Hospital and Oyokyo Kidney Research Institute were included. Among them, 19 underwent PKT and 81 patients underwent pretransplant dialysis. We retrospectively compared pretransplant and post-transplant aortic calcification index (ACI), renal function (estimated glomerular filtration rate [eGFR]), and graft and cardiovascular event-free survivals between the 2 groups. RESULTS The median age of this cohort was 45 years. Preoperative ACI was significantly lower in PKT recipients. There were no significant differences between the 2 groups regarding postoperative eGFR, graft survival, and cardiovascular event-free survival. However, the ACI progression rate (ΔACI/y) was significantly lower in PKT recipients than in those who underwent pretransplant dialysis. Higher ACI was significantly associated with poor cardiovascular event-free survival. CONCLUSIONS PKT is beneficial in that it contributes to the slow progression of after transplantation. Although we could not observe significant differences in graft and cardiovascular event-free survivals between the 2 groups, slow progression of aortic calcification showed a potential to decrease cardiovascular events in PKT recipients during long-term follow-up.
Case reports in urology | 2018
Hirotake Kodama; Shingo Hatakeyama; Teppei Matsumoto; Toshikazu Tanaka; Hirotaka Horiguchi; Yuka Kubota; Hayato Yamamoto; Atsushi Imai; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama
A paratesticular fibrous pseudotumor is a relatively rare benign disease. Preoperatively diagnosing a fibrous pseudotumor is challenging because distinguishing these masses from malignant tumors on the basis of clinical and radiological findings can be difficult. We present a case of a 28-year-old man who presented with a painless palpable mass in the right scrotum; the fibrous pseudotumor of the tunica vaginalis was treated with organ-sparing surgery. Computed tomography and magnetic resonance imaging revealed paratesticular tumors. Testicular tumor marker levels were within normal limits. We scheduled the patient to undergo tumor biopsy combined with intraoperative rapid diagnosis. Frozen section assessment suggested a fibrous pseudotumor without malignancy. We successfully performed organ-sparing surgery. Testicular-sparing surgery combined with frozen section assessment is primarily used for treating paratesticular fibrous pseudotumors.
BJUI | 2018
Teppei Matsumoto; Shingo Hatakeyama; Atsushi Imai; Toshikazu Tanaka; Kazuhisa Hagiwara; Sakae Konishi; Kazutaka Okita; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Shigeyuki Nakaji; Chikara Ohyama
To investigate the relationship between oxidative stress and lower urinary tract symptoms (LUTS) in a community‐dwelling population.
The Journal of Urology | 2017
Shingo Hatakeyama; Osamu Soma; Takuma Narita; Kazuhisa Tanaka; Toshikazu Tanaka; Daisuke Noro; Masaaki Oikawa; Yoshimi Tanaka; Teppei Matsumoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama
INTRODUCTION AND OBJECTIVES: Frailty, defined as a measure of decreased physiologic reserve, is strongly associated with increased susceptibility to disability and poor outcomes. The purpose of this study was to describe the extent of frailty among patients with various urologic diagnoses and to explore whether or not frailty differed between patients who did and did not undergo urologic surgery. METHODS: This is a prospective study of men and women ages 65 and older presenting to an academic non-oncologic urology practice between December 2015 and May 2016. Frailty was measured in individuals via the Timed Up and Go Test (TUGT) upon intake. Based on the TUGT, individuals were classified as not frail (1⁄410 sec), intermediately frail (11-14 sec) or frail (1⁄415 sec). The TUGT and other clinical data were abstracted from the electronic medical record using EPIC analytical software into an on-going database. TUGT values were reported overall, by urologic diagnosis, and according to whether or not they were associated with a urologic procedure. RESULTS: There were 1089 unique individuals who presented to our practice and had a TUGT during the study period. Among these individuals, the mean age was 73.3 ( 6.3) years, 77.6% were male, 64.7% were white and the mean TUGT was 11.6 ( 6.0) seconds, with 30.0% and 15.2% classified as intermediately frail and frail, respectively. TUGT time (and hence frailty) increased linearly with increasing age (Figure). TUGT values differed by urologic diagnosis ranging from 9.9 ( 3.0) seconds among individuals with general male urology diagnoses to 14.3 ( 11.9) seconds among individuals with urinary tract infections (UTIs). There were no statistically significant differences in TUGT values between individuals who did and did not undergo urologic surgery. CONCLUSIONS: Frailty is common, increases with age, and varies based on urologic diagnosis among individuals presenting to an academic non-oncologic urology practice. Interestingly, frailty did not differ between individuals who did and did not undergo urologic surgery, suggesting that there is a potential opportunity to incorporate frailty into the perioperative decision-making process. Since frailty is prevalent among urologic patients and linked to poor outcomes, consideration of frailty in the surgical decision-making process is warranted and may improve outcomes. Source of Funding: NIDDK K12 DK83021-07
Medical Oncology | 2017
Teppei Matsumoto; Shingo Hatakeyama; Teppei Ookubo; Koji Mitsuzuka; Shintaro Narita; Takamitsu Inoue; Shinichi Yamashita; Takuma Narita; Takuya Koie; Sadafumi Kawamura; Tatsuo Tochigi; Norihiko Tsuchiya; Tomonori Habuchi; Yoichi Arai; Chikara Ohyama
The aim of the present study was to assess the cost-effectiveness of extended pelvic lymph node dissection (ePLND) compared to neoadjuvant chemohormonal therapy using gonadotropin-releasing hormone agonist/antagonist and estramustine. We retrospectively analyzed data within Michinoku Urological Cancer Study Group database containing 2971 PC patients treated with radical prostatectomy (RP) at four institutes between July 1996 and July 2017. We identified 237 and 403 high-risk patients who underwent RP and ePLND (ePLND group), and neoadjuvant chemohormonal therapy followed by RP and limited PLND (neoadjuvant group), respectively. The oncological outcomes and cost-effectiveness were compared between groups. Medical cost calculation focused on PC-related medication and adjuvant radiotherapy. Biochemical recurrence-free and overall survival rates in the neoadjuvant group were significantly higher than those in the ePLND group. Significantly higher number of patients progressed to castration-resistant PC in the ePLND group than in the neoadjuvant group. Background-adjusted multivariate Cox regression analysis using inverse probability of treatment weighting (IPTW) revealed that neoadjuvant chemohormonal therapy independently reduced the risk of biochemical recurrence after RP. The 5-year cost per person was significantly higher in the ePLND group than in the neoadjuvant group. Although the present study was retrospective, neoadjuvant chemohormonal therapy followed by RP as a concurrent strategy has potential to improve oncological outcome and cost-effectiveness.